This review highlights NK-1R as being an important therapeutic target and outlines important studies that highlight the potentiality of NK-1R antagonists, such as aprepitant as a possible therapeutic agent in osteosarcoma patients. The gene discussed is TACR1; the disease is osteosarcoma.